Mar. 3rd, 2017. (BUSINESS WIRE) – Cerveau Technologies, Inc. today announced a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Disease Research Center to support various research projects studying the stages of Alzheimer’s Disease and other neurodegenerative diseases. These research projects will utilize an early stage imaging agent (MK-6240) to be used in Positron Emission […]
Cerveau Technologies, Inc. today announced finalization of an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of Merck’s early stage investigational imaging agent (MK-6240) being evaluated for use in Positron Emission Tomography (PET) scans to image neurofibrillary tangles (NFTs) in the brain. NFTs made […]
Sept. 28th, 2016. Mr. Xu Xinsheng and Mr. Chu Wei, the President and COO of Sinotau Pharmaceuticals Group, had a highly fruitful meeting with Professor Serge Gauthier, McGill University (Canada), Mr. Rick Hiatt, CEO of the Canadian company Enigma, and a selected group of Chinese Pharma experts. Alzheimer’s disease was the main issue discussed during […]